Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer
暂无分享，去创建一个
M. Malim | A. Hayday | S. Irshad | B. North | C. Graham | K. Doores | T. Tree | S. Papa | K. Owczarczyk | P. Fields | L. Monin | M. Muñoz-Ruiz | Duncan R. McKenzie | Sultan Abdul-jawad | J. Seow | P. Patten | A. Swampillai | R. Graham | E. Pollock | Thanussuyah Alaguthurai | J. Vidler | H. Kristeleit | Kamila Sychowska | T. Lechmere | Catherine Tremain | C. Gousis | C. Domingo-Vila | J. Cooper | Sultan Abdul-Jawad | Jennifer Vidler
[1] Patrick W. Johnson,et al. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies , 2021, Cancer Cell.
[2] A. Addeo,et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer , 2021, Cancer Cell.
[3] K. Pradhan,et al. Seroconversion rates following COVID-19 vaccination among patients with cancer , 2021, Cancer Cell.
[4] K. Pradhan,et al. Seroconversion rates following COVID-19 vaccination amongst patients with malignant disease- the impact of diagnosis and cancer-directed therapies , 2021, medRxiv.
[5] M. Malim,et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study , 2021, The Lancet Oncology.
[6] A. Coolen,et al. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients , 2021, Cancer Cell.
[7] J. Warner,et al. COVID-19 and Cancer: Current Challenges and Perspectives , 2020, Cancer Cell.